Literature DB >> 2930692

Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.

R A Cowan1, M Jones, M Harris, W P Steward, J A Radford, J Wagstaff, D P Deakin, D Crowther.   

Abstract

An analysis of prognostic factors has been performed on 260 patients with high and intermediate grade non-Hodgkin's lymphoma (NHL) treated over an 11-year period between 1975 and 1986. The overall 5-year survival rate was 50% with a median follow-up of 72 months. Over 20 clinical, radiological and laboratory parameters have been studied, including variables reported to be important indicators of prognosis in previous series, and these variables have been subjected to univariate and multivariate analysis. Attainment of complete remission (CR) was the most important predictor of overall survival, low serum lactate dehydrogenase (LDH), limited stage disease and a high serum albumin were also independently associated with prolonged survival in multivariate analysis. After removing remission status from the model, Ann Arbor clinical stage became the most significant pre-treatment prognostic indicator. Sixty-five per cent of patients achieved CR, and a discriminant analysis showed that failure to attain CR was associated with advanced stage disease, constitutional symptoms, increasing patient age, a low serum albumin and the presence of bulk disease. Advanced clinical stage and an elevated serum LDH predicted independently for a poor relapse-free survival, and reduced overall survival following CR. There was no significant correlation between histological subtype in the Kiel classification and prognosis. This study confirms the prognostic significance of remission status and Ann Arbor clinical stage, and illustrates additional factors including serum levels of albumin and LDH, which serve to enhance the pre-treatment prognostic evaluation of patients with unfavourable histology NHL.

Entities:  

Mesh:

Year:  1989        PMID: 2930692      PMCID: PMC2247014          DOI: 10.1038/bjc.1989.57

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Correlation of serum lactic dehydrogenase activity with the clinical status of patients with cancer, lymphomas, and the leukemias.

Authors:  H R BIERMAN; B R HILL; L REINHARDT; E EMORY
Journal:  Cancer Res       Date:  1957-08       Impact factor: 12.701

2.  The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group.

Authors:  B N Nathwani; D O Dixon; S E Jones; R J Hartsock; J W Rebuck; G E Byrne; W W Sheehan; H Kim; C A Coltman; H Rappaport
Journal:  Blood       Date:  1982-11       Impact factor: 22.113

3.  Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables.

Authors:  B Koziner; C Little; S Passe; H T Thaler; R Sklaroff; D J Straus; B J Lee; B D Clarkson
Journal:  Cancer       Date:  1982-04-15       Impact factor: 6.860

4.  Intensive combination chemotherapy with vincristine, adriamycin and prednisolone (VAP) in the treatment of diffuse histology non-Hodgkin's lymphoma. (A report of 89 cases with extensive disease from the Manchester Lymphoma Group).

Authors:  G Blackledge; H Bush; J Chang; D Crowther; D P Deakin; O G Dodge; J V Garrett; M Palmer; D Pearson; J H Scarffe; I D Todd; P M Wilkinson
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

5.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

6.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Authors:  R I Fisher; V T DeVita; S M Hubbard; D L Longo; R Wesley; B A Chabner; R C Young
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

7.  Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphoma.

Authors:  H Hagberg; A Siegbahn
Journal:  Scand J Haematol       Date:  1983-07

8.  Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas.

Authors:  A M Ferraris; P Giuntini; G F Gaetani
Journal:  Blood       Date:  1979-10       Impact factor: 22.113

9.  Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma.

Authors:  D L Sweet; H M Golomb; J E Ultmann; J B Miller; R S Stein; E P Lester; U Mintz; J D Bitran; R A Streuli; K Daly; N O Roth
Journal:  Ann Intern Med       Date:  1980-06       Impact factor: 25.391

10.  Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.

Authors:  R I Fisher; S M Hubbard; V T DeVita; C W Berard; R Wesley; J Cossman; R C Young
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

View more
  8 in total

Review 1.  Non-Hodgkin Lymphoma Metabolism.

Authors:  Brian James Kirsch; Shu-Jyuan Chang; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

2.  Colorectal lymphoma.

Authors:  Frank J Quayle; Jennifer K Lowney
Journal:  Clin Colon Rectal Surg       Date:  2006-05

3.  Diffuse large B-cell lymphoma: experience from a tertiary care center in North India.

Authors:  Rohan Khera; Snigdha Jain; Lalit Kumar; S Thulkar; M Vijayraghwan; R Dawar
Journal:  Med Oncol       Date:  2009-04-07       Impact factor: 3.064

4.  Serum Lactate Dehydrogenase in Non-Hodgkin's Lymphoma: A Prognostic Indicator.

Authors:  Charu Yadav; Afzal Ahmad; Benedicta D'Souza; Ashish Agarwal; M Nandini; K Ashok Prabhu; Vivian D'Souza
Journal:  Indian J Clin Biochem       Date:  2015-06-21

5.  Non-Hodgkin Lymphoma Metabolism.

Authors:  Brian James Kirsch; Shu-Jyuan Chang; Michael James Betenbaugh; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  DNA content in high and intermediate grade non-Hodgkin's lymphoma-prognostic significance and clinicopathological correlations.

Authors:  R A Cowan; M Harris; M Jones; D Crowther
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

7.  Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.

Authors:  H S Dhaliwal; A Z Rohatiner; W Gregory; M A Richards; P W Johnson; J S Whelan; C J Gallagher; J Matthews; T S Ganesan; M J Barnett
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

8.  Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study.

Authors:  J H Youngson; J M Jones; J G Chang; M Harris; S S Banergee
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.